Skip Nav Destination
Issues
1 July 2013
-
Cover Image
Cover Image
Head and neck squamous cell carcinomas (HNSCC) are a genetically heterogeneous group of cancers with a poor survival rate. Lui and colleagues evaluated the mutation frequency of mitogenic pathways in HNSCCs and found that 30.5% of tumors harbored PI3K pathway mutations. Patient-derived tumorgrafts with hotspot and noncanonical PIK3CA mutations were highly sensitive to PI3K inhibitors. Pickering and colleagues performed integrated genomic analyses of oral squamous cell carcinomas (OSCC), a particularly lethal, poorly characterized HNSCC sub-type. The Notch pathway was deregulated in 66% of OSCCs, and inactivation of NOTCH1 was shown to drive OSCC growth. Common inactivating mutations of FAT1 and CASP8 were also identified. Together, these findings provide insight into the etiology of HNSCC and identify potential therapeutic targets. For details, please see the article by Lui and colleagues on page 761 and the article by Pickering and colleagues on page 770. - PDF Icon PDF LinkTable of Contents
ISSN 2159-8274
EISSN 2159-8290
Issue Sections
In This Issue
In the Spotlight
Review
Research Briefs
Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors
Erick J. Morris; Sharda Jha; Clifford R. Restaino; Priya Dayananth; Hugh Zhu; Alan Cooper; Donna Carr; Yongi Deng; Weihong Jin; Stuart Black; Brian Long; Jenny Liu; Edward DiNunzio; William Windsor; Rumin Zhang; Shuxia Zhao; Minilik H. Angagaw; Elaine M. Pinheiro; Jagdish Desai; Li Xiao; Gerald Shipps; Alan Hruza; James Wang; Joe Kelly; Sunil Paliwal; Xiaolei Gao; Boga Sobhana Babu; Liang Zhu; Pierre Daublain; Ling Zhang; Bart A. Lutterbach; Marc R. Pelletier; Ulrike Philippar; Phieng Siliphaivanh; David Witter; Paul Kirschmeier; W. Robert Bishop; Daniel Hicklin; D. Gary Gilliland; Lata Jayaraman; Leigh Zawel; Stephen Fawell; Ahmed A. Samatar
Author Choice
Frequent Mutation of the PI3K Pathway in Head and Neck Cancer Defines Predictive Biomarkers
Vivian W.Y. Lui; Matthew L. Hedberg; Hua Li; Bhavana S. Vangara; Kelsey Pendleton; Yan Zeng; Yiling Lu; Qiuhong Zhang; Yu Du; Breean R. Gilbert; Maria Freilino; Sam Sauerwein; Noah D. Peyser; Dong Xiao; Brenda Diergaarde; Lin Wang; Simion Chiosea; Raja Seethala; Jonas T. Johnson; Seungwon Kim; Umamaheswar Duvvuri; Robert L. Ferris; Marjorie Romkes; Tomoko Nukui; Patrick Kwok-Shing Ng; Levi A. Garraway; Peter S. Hammerman; Gordon B. Mills; Jennifer R. Grandis
Research Articles
Integrative Genomic Characterization of Oral Squamous Cell Carcinoma Identifies Frequent Somatic Drivers
Curtis R. Pickering; Jiexin Zhang; Suk Young Yoo; Linnea Bengtsson; Shhyam Moorthy; David M. Neskey; Mei Zhao; Marcus V. Ortega Alves; Kyle Chang; Jennifer Drummond; Elsa Cortez; Tong-xin Xie; Di Zhang; Woonbok Chung; Jean-Pierre J. Issa; Patrick A. Zweidler-McKay; Xifeng Wu; Adel K. El-Naggar; John N. Weinstein; Jing Wang; Donna M. Muzny; Richard A. Gibbs; David A. Wheeler; Jeffrey N. Myers; Mitchell J. Frederick
Diacylglycerol Kinase α Is a Critical Signaling Node and Novel Therapeutic Target in Glioblastoma and Other Cancers
Charli L. Dominguez; Desiree H. Floyd; Aizhen Xiao; Garrett R. Mullins; Benjamin A. Kefas; Wenjun Xin; Melissa N. Yacur; Roger Abounader; Jae K. Lee; Gabriela Mustata Wilson; Thurl E. Harris; Benjamin W. Purow
Author Choice
Selective Estrogen Receptor Modulators and Pharmacogenomic Variation in ZNF423 Regulation of BRCA1 Expression: Individualized Breast Cancer Prevention
James N. Ingle; Mohan Liu; D. Lawrence Wickerham; Daniel J. Schaid; Liewei Wang; Taisei Mushiroda; Michiaki Kubo; Joseph P. Costantino; Victor G. Vogel; Soonmyung Paik; Matthew P. Goetz; Matthew M. Ames; Gregory D. Jenkins; Anthony Batzler; Erin E. Carlson; David A. Flockhart; Norman Wolmark; Yusuke Nakamura; Richard M. Weinshilboum
News in Brief
News in Depth
Research Watch
Chemotherapy
Clinical Trials
Colorectal Cancer
DNA Damage
DNA Repair
Drug Development
Drug Resistance
Glioblastoma
Immunotherapy
Leukemia
Metabolism
Metastasis
Oncogenes
Risk Factors
Senescence
Signaling
Splicing
Targeted Therapy
Tumor Suppressors
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.